PYXSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Pyxis Oncology, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 13, 2026
$1.76+0.08 (+4.76%)
Close on Oct 19, 2026
- Market cap
- $112.63M
- P/E (TTM)
- –
- Dividend yield
- –
Pyxis Oncology, Inc. revenue by segment
By business segment
By product or service
| Revenue | Q2 26 | Q4 25 | Q3 25 | Q2 25 | Q1 25 | Q4 24 | Q3 24 | Q2 24 | Q1 24 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Milestone Revenue | $0 | $0 | $0 | $2.82M | – | – | – | – | – | – | -100.0% |
| Royalty Revenues | – | – | – | – | – | $0 | $0 | $0 | $8.15M | – | – |
| Sale of Royalty Rights | – | – | – | – | – | $0 | $0 | $0 | $8.00M | – | – |
| Royalty revenue and sale of royalty rights | – | – | – | – | $0 | – | – | – | $16.15M | – | – |
| Milestone revenue, royalty revenue and sale of royalty rights | – | – | $0 | $2.82M | – | – | $0 | $0 | – | – | – |
By region
From the segment and revenue-disaggregation notes of Pyxis Oncology's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.